Lifestance Health Group (LFST) PT Raised at KeyBanc as 'Clinician Productivity Drives Strong Quarter'

KeyBanc analyst Steve Dechert raised the price target on Lifestance Health Group (NASDAQ: LFST) to $9.00 (from $8.50) while maintaining an Overweight rating.

The analyst commented: "Clinician Productivity Drives Strong Quarter; MidTeens Adj. EBITDA Margins Expected by FY28; LFST reported a top & bottom-line beat with 4Q adj. EBITDA ~21% above consensus and clinician productivity up an impressive ~7%. We expect continued clinician productivity growth in FY26 from its new care-matching algorithm/tool (already seeing improved conversion/stickiness) as well as the rollout of its new AI clinical documentation tool. LFST also announced an adj. EBITDA margin outlook of mid-teens adj. EBITDA margins by 2028 that coincided with FY26 adj. EBITDA guidance that was ~7.3% above consensus. We raise estimates and our PT to $9.00 as a result."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• New Street Research Upgrades Micron Technology (MU) to Buy
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results